Mechanism of immune-suppression causing Bevacizumab resistance in ovarian cancer
| Project/Area Number |
15K20140
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Abiko Kaoru 京都大学, 医学研究科, 助教 (20508246)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 卵巣癌 / 骨髄由来抑制性細胞 / 低酸素 / VEGF / 抗腫瘍免疫 / 骨髄由来制御性細胞 / MDSC |
|---|
| Outline of Final Research Achievements |
We explored the mechanisms of resistance to anti-VEGF therapy in ovarian cancer. In mouse models, anti-VEGF-antibody-resistant tumor showed larger hypoxic area and higher expression levels of GM-CSF. GM-CSF enhanced the production and immune-suppressive property of Myeloid Derived Suppressor Cells (MDSC) from myeloid cells. Our data indicated that targeting the hypoxia-induced cytokine, GM-CSF, may overcome the resistance to antiangiogenic therapy in ovarian cancer.
|
Report
(3 results)
Research Products
(8 results)
